Friday, 20 Apr 2018

You are here

My ACR Takeaways

With ACR 2017 winding down and the sheer volume of information seemingly overwhelming, I wanted to take the time to write an article regarding a few tips I learned that I will use in clinical practice. 

1. With regards to the flu vaccine, holding MTX for two weeks after the flu vaccine will increase immunogenicity without worsening disease. 
2. CAPS is a complementopathy and Eculizumab (anti-C5a) is approved for treatment, though is expensive
3. 1% of GPA patients can present with pituitary involvement and respond to Cytoxan or Rituxan
4. HCQ should be a mainstay in APS therapy – can reduce size of thrombus and number of potential events. 
5. MMF at 3 grams is not superior to 2 grams in rheum-related ILD
6. RA and SpA remission patients fare better with continued therapy than with withdrawal 
7. A healthy mom is the best thing for a healthy baby in terms of safety of continuing DMARDs and bDMARDs during pregnancy and lactation. 
8. Options for MACRA and MIPs data submission supported by ACR include the RISE registry and RCR

While this list barely scratches the surface, it’s a helpful start to digesting data from ACR to use for our day to day practice. I’m looking forward to hearing more about upcoming guidelines, updated diagnostic criteria, telemedicine, and US advances in both the education and diagnostic realms. 

Until Chicago!

 


Rheumatologists' Comments

Dear Rachel Tate, it´s a fantastic compilation of the ACR on what we should start (or keep) doing. Congratulations, Carlos Antonio Moura

More Like This

The RheumNow Week in Review – Vitamin D Snark Report (4.20.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.  A second life for Syk kinase, Vitamin D talk, VTE, regulatory hearings and the Lupus clinic edge.

RheumNow Week in Review - Do you Dig Shingrix? (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. Highlights includes manpower shortfalls, comorbidities in AA Lupus, certolizumab pregnancy safety, which Shingles vaccine is best and the power of combination biologics in severe refractory  SLE.

"Breakthrough" Drug Designation by the FDA

The current issue of the NEJM reviews the Food and Drug Administration (FDA) “breakthrough therapy” designation that was introduced in 2012 to expedite testing and approval of medications that were intended to treat serious or life-threatening conditions.  This status is granted when preliminary evidence with a new drug suggests substantial benefits over existing therapies for these unfortunate conditions.

ACR Projects Significant Manpower Shortages for 2030

Arthritis & Rheumatology has published the results of the 2015 Workforce Study of Rheumatology Specialists, and estimates a current shortage (demand > supply) of 700 (12.9%) full-time rheumatologists and that this deficit will worsen (102%) to 4133 FTE by 2030.

RheumNow Week in Review -The Temporal Artery Biopsy Letdown (4.6.2018)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. News on the cost of RA care, infections on planes, CV events and Sacroiliitis in IBD, NXP-2 antibodies and calcinosis and rituximab in myositis ILD patients.